The Price of a Life: Unveiling the Struggle of Living With Hereditary Angioedema

Hereditary angioedema (HAE) is a rare, autosomal dominant genetic disorder characterized by recurrent episodes of localized swelling in various body tissues. It is caused by mutations in the C1 inhibitor gene, leading to dysregulation of the complement and contact systems. This results in excessive bradykinin production and increased vascular permeability leading to subcutaneous and cutaneous edema. Despite advances in understanding HAE pathophysiology and the development of effective treatment and prevention strategies, the management of this condition remains a challenge due to the high cost that limits access to these medications for some patients. Through a detailed case report, the authors aim to shed light on the struggles faced by individuals with HAE and their difficulty in affording life-saving medications. Several studies have documented the financial challenges faced by individuals with HAE, including high average annual costs and difficulties affording medications. Addressing medication affordability in HAE requires a multifaceted approach involving regulatory bodies, healthcare providers, pharmaceutical manufacturers, and policymakers. This case report highlights multiple ICU admissions within a short timeframe where medication affordability played a role, and secondarily presents what appears to be the first reported case of cocaine inducing HAE episodes.

Prior research has detailed the substantial economic burden of HAE. Reports cite average annual costs per patient around $42,000 and up to $96,000 for severe attacks requiring hospitalization and emergency department care, with on-demand-only treatment estimated as high as $363,795 annually. Approximately 76% of patients report difficulty affording HAE medications, and physicians identify insurance coverage and cost as major factors influencing treatment and prophylaxis choices. These financial barriers can worsen outcomes by increasing healthcare utilization, hospitalization, and ICU stays.

Case report of a 47-year-old male with a 16-year history of HAE who presented with acute facial swelling involving both eyes, philtrum, and upper lip. Prehospital treatment included dexamethasone, diphenhydramine, and famotidine. In the emergency department, he received tranexamic acid. Labs were unremarkable except for a urine drug screen (UDS) positive for cocaine, low C4, and C1 esterase inhibitor activity of 100%. CT neck imaging showed superficial subcutaneous edema without airway compromise. He was admitted to the ICU for observation and discharged the next day with danazol 200 mg twice daily for prophylaxis and scheduled for allergy/immunology follow-up. On the day of the scheduled visit, he re-presented with shortness of breath and stridor, required emergent intubation, and was admitted to the ICU; he did not receive C1 esterase inhibitor in the ED prior to intubation. Labs again showed a positive UDS for cocaine and, this time, cannabinoids. Helicobacter pylori screening was negative. He was counseled to abstain from cocaine and discharged with another allergy/immunology follow-up and the same prophylaxis while social services pursued a county assistance program for a year of free IV C1 esterase inhibitor. The patient did not attend outpatient follow-up despite qualifying for free care and medications. Eight months later, he returned with shortness of breath and stridor; he was not intubated, and ED documentation did not list any home HAE medications (including danazol or IV C1 esterase inhibitor previously approved). The case narrative explores the clinical course, suspected triggers, barriers to care, and the role of affordability and adherence.

• Recurrent, potentially life-threatening HAE attacks led to multiple ICU admissions and at least one intubation within a short period.
• Laboratory findings during an acute episode included low C4 with C1 esterase inhibitor activity at 100%; repeated urine drug screens were positive for cocaine (and once also cannabinoids).
• CT neck imaging demonstrated superficial subcutaneous edema without airway compromise during the index presentation.
• The patient experienced significant barriers to accessing and adhering to recommended HAE prophylaxis (danazol, C1 esterase inhibitor), including missed outpatient appointments despite approval for assistance programs.
• Authors highlight what appears to be the first reported case of cocaine as a trigger for HAE episodes, supported by repeated positive cocaine UDS temporally associated with flares and literature on cocaine-associated angioedema in non-HAE patients.
• Literature cited indicates substantial economic burden of HAE: average annual cost per patient about $42,000 and up to $96,000 for severe attacks; on-demand-only treatment costs up to $363,795 annually; approximately 76% of patients report difficulty affording medications; physicians report cost and insurance coverage as primary drivers of treatment selection.

The case underscores the intersection of HAE pathophysiology with real-world barriers to care. HAE arises from deficiency or dysfunction of C1 inhibitor leading to excessive bradykinin, increased vascular permeability, and edema; targeted therapies such as C1-INH replacement and bradykinin-pathway agents can reduce attack frequency and severity. However, high medication costs limit access and adherence, potentially resulting in more frequent severe attacks, ICU admissions, and intubations as seen in this patient. The repeated positive cocaine screens and timing of flares, together with literature documenting cocaine-induced angioedema (e.g., Quincke’s disease) in individuals without HAE, suggest cocaine may have served as a trigger in this HAE patient, representing a novel association. The case highlights the need for inpatient allergy/immunology evaluation for patients with newly diagnosed HAE, frequent flares, or high risk of being lost to follow-up, and emphasizes system-level solutions (competition, price negotiation, assistance programs) to improve affordability and outcomes.

This case brings attention to the high costs of lifesaving HAE medications and the need for more accessible options and patient assistance programs so patients can obtain necessary therapies without financial hardship. It also emphasizes the value of inpatient allergy/immunology evaluation in patients at high risk of loss to follow-up. Additionally, it presents the first reported case of HAE episodes triggered by cocaine use, underscoring the importance of addressing substance use in HAE management.

• Single-patient case report limits generalizability and causal inference regarding cocaine as a trigger.
• The association between cocaine use and HAE flares is inferred from temporal correlation and prior reports of cocaine-related angioedema in non-HAE patients; mechanistic confirmation is lacking.
• Patient nonadherence and missed outpatient follow-up limited comprehensive outpatient evaluation and consistent prophylaxis, constraining longitudinal assessment of triggers and treatment response.
• Real-world factors (access, affordability, social determinants) confound interpretation of outcomes.